Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Zurich
This study evaluates the administration of T-VEC in non-melanoma skin cancer. The aim is to evaluate the effectiveness, safety and tolerability of T-VEC in patients with non-melanoma skin cancer through determination of local immune effects after repeated T-VEC injections.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects Age ≥ 18 years
histologically confirmed diagnosis of locally advanced squamous cell carcinoma, basal cell, carcinoma, Merkel cell carcinoma or cutaneous T cell lymphoma
at least 1 injectable cutaneous lesion ≥ 20 mm in longest Diameter or multiple injectable lesions that in Aggregate have a longest Diameter of ≥ 50 mm
Eastern Cooperative Oncology Group-Status (ECOG Status) 0 or 1
Adequate organ functions
You may not be if
Hypersensitivity to T-VEC or any of ist components
Presence of organ and lymph node metastases
history or evidence of active autoimmune disease that requires systemic Treatment
Evidence of clinically significant immunosuppression
active herpetic skin lesions or prior complications hereof
pregnancy, breast feeding
requires intermittent or chronic systemic Treatment with an antiherpetic drug
acute or chronic active Hepatitis B or C infection or HIV infection
